NeoStem, Inc. (NBS) Receives Two-Year $1.2 Million NIH Grant for First Clinical Study of VSEL Technology in Humans
NeoStem is a firm engaged in the fast growing cell therapy industry. This industry is expected to have a significant role in the future in the fight against chronic disease. The company’s contract development and manufacturing service business, Progenitor Cell Therapy LLC, supports the development of proprietary cell therapy products. The company today announced that it has been awarded a two-year grant totaling $1,221,854 from the National Institute of Dental and Craniofacial Research, a division of the National Institute of Health (NIH). The grant was for “Repair of Bone Defects With Human Autologous Pluripotent Very Small Embryonic-Like Stem Cells (VSEL)”.…